1. Home
  2. LAB vs LYEL Comparison

LAB vs LYEL Comparison

Compare LAB & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standard BioTools Inc.

LAB

Standard BioTools Inc.

HOLD

Current Price

$0.92

Market Cap

354.1M

Sector

Industrials

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$23.70

Market Cap

556.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAB
LYEL
Founded
1999
2018
Country
United States
United States
Employees
N/A
161
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
354.1M
556.1M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
LAB
LYEL
Price
$0.92
$23.70
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$1.35
$30.60
AVG Volume (30 Days)
2.6M
74.3K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
61.54
N/A
EPS
N/A
N/A
Revenue
$101,937,000.00
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.63
$16,285.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.39
52 Week High
$1.72
$45.00

Technical Indicators

Market Signals
Indicator
LAB
LYEL
Relative Strength Index (RSI) 45.23 55.08
Support Level $0.92 $21.27
Resistance Level $1.01 $27.30
Average True Range (ATR) 0.05 1.71
MACD 0.01 0.43
Stochastic Oscillator 48.54 74.68

Price Performance

Historical Comparison
LAB
LYEL

About LAB Standard BioTools Inc.

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: